Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63.
Pigs were vaccinated by scarification or intramuscular injection with a swinepox virus-Aujeszky's disease (pseudorabies) recombinant (rSPV-AD) constructed by inserting the linked Aujeszky's disease virus genes coding for glycoproteins gp50 and gp63, attached to a vaccinia virus p7.5 promoter, into the thymidine kinase gene of swinepox virus. By 21 days after vaccination, 90 and 100 per cent of the animals vaccinated by scarification or intramuscular injection, respectively, had developed serum neutralising antibodies to Aujeszky's disease virus. Upon challenge with virulent virus, significantly fewer vaccinated pigs developed clinical Aujeszky's disease, nasal shedding of challenge virus was markedly reduced, and the vaccinated groups of pigs maintained or gained weight during the week after challenge whereas the unvaccinated control group lost weight. No transmission of rSPV-AD to in-contact controls was detected during the three weeks before challenge. In a second experiment, serum neutralising antibodies to Aujeszky's disease virus persisted for 150 days after the pigs were vaccinated with rSPV-AD by scarification or intramuscular injection and all the pigs showed an anamnestic response when they were revaccinated.
van der Leek
M L
ML
College of Veterinary Medicine, University of Florida, Gainesville 32611.
Feller
J A
JA
Sorensen
G
G
Isaacson
W
W
Adams
C L
CL
Borde
D J
DJ
Pfeiffer
N
N
Tran
T
T
Moyer
R W
RW
Gibbs
E P
EP
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002460:Cell Line; D005069:Evaluation Studies as Topic; D011558:Herpesvirus 1, Suid / Q000235:genetics* / Q000276:immunology / Q000302:isolation & purification; D008297:Male; D011557:Pseudorabies / Q000276:immunology / Q000517:prevention & control*; D018148:Suipoxvirus / Q000235:genetics* / Q000276:immunology; D013552:Swine; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology; D017201:Virus Shedding
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins